About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
https://weizmann-usa.org/news-media/news-releases/plant-research-reaches-a-new-high/
Apr 30, 2023... REHOVOT, ISRAEL—May 1, 2023—A South African plant called a woolly umbrella is completely unrelated to the cannabis plant, yet it makes a slew of the active compounds found in cannabis – cannabinoids – including some that may have new medical uses. In a study published today in Nature Plants, Weizmann Institute of Science researchers identified more than 40 cannabinoids in the woolly umbrella, and they revealed the series of biochemical steps the plant takes when it makes these compounds. The researchers also showed how these steps can be reproduced in the lab to synthesize or even engineer new cannabinoids.
Aug 02, 2023... REHOVOT, ISRAEL—August 2, 2023—Scientific excellence requires diversity – research conducted by people from different backgrounds and with varied worldviews. The need for diversity extends to scientific experiments themselves, but the vast majority of studies in the life sciences are conducted using male mice only, which could not only bias the findings, but impede our ability to extrapolate from them to humans. A new study by researchers from the Weizmann Institute of Science addresses this challenge, revealing in unprecedented detail how the brains of male and female mice respond differently to stress.
Aug 07, 2023...
REHOVOT, ISRAEL — August 8, 2023—Nonsmokers who develop lung cancer can be treated effectively with new drugs, but their tumors refuse to surrender without a fight. The drugs stop working in the long term because the tumors acquire secondary mutations that allow them to evade the medications’ therapeutic effect.
In research published today in the journal Cell Reports Medicine, investigators from the Weizmann Institute of Science report findings that may lead to relapse-free treatment for a sizeable subgroup of lung cancer patients. In a study in mice, scientists identified a biomarker that may help physicians treat select lung cancer patients with a single antibody-based drug that is likely to bring about full remission, without cancer relapse.
Aug 08, 2023...
To protect itself against disease, the human body has immune cells that patrol like police officers, entering disease cells and destroying them. But some dangerous cells, including some solid tumors, operate in stealth and cannot be targeted by the body’s regular immune system.
Edity Therapeutics, an Israeli startup founded in 2019, reprograms a patient’s own immune cells, giving them the ability to hunt down and destroy these cancer cells. It’s like transforming regular beat cops into lethal supersleuths.
Aug 08, 2023... Israeli study finds biological treatment effective for lung cancer
Nov 10, 2023... REHOVOT, ISRAEL—November 10, 2023—An international crowdsourced campaign to discover an anti-COVID-19 drug has created a blueprint for the accelerated, patent-free development of drugs to treat viral threats to humanity. The campaign, called COVID Moonshot, was co-led by Prof. Nir London of the Weizmann Institute of Science and researchers from the University of Oxford, Memorial Sloan Kettering Cancer Center, and the US-based biotech company PostEra. The results have been published in Science.
Dec 18, 2023... REHOVOT, ISRAEL—December 19, 2023 — For decades, it has been known that people with diabetes are at a substantially increased risk of developing severe lung disease if they become infected with viruses such as influenza, as well as with bacteria or fungi. When the COVID-19 pandemic started in early 2020, this mysterious phenomenon took on even greater importance: It became clear that people with diabetes were at significantly higher risk of severe – or even fatal – lung disease after becoming seriously ill from the virus. In fact, 35% of people with COVID-19 who died during the pandemic had diabetes, but no one understood why.
Jan 18, 2024... REHOVOT, ISRAEL—January 18, 2024—Winning a battle requires precise intelligence and unwavering resolve. But when it comes to the battle against cancer, the immune system’s soldiers – called T cells – quickly become exhausted, and intelligence-providing dendritic cells are scarce. This is one of the reasons why the great promise of immunotherapy – a new generation of treatments that harness the body’s own immune system to fight cancer – has not been fully realized.
https://weizmann-usa.org/news-media/news-releases/toward-a-treatment-for-huntington-s-disease/
Feb 27, 2024...
REHOVOT, ISRAEL—February 27, 2024—The human brain is a well-guarded control center. Its system of blood vessels is surrounded by a densely packed cellular barrier that prevents most substances from getting in or out. This fortified architecture protects the brain, but it can also stop it from getting help when needed – as in the case of a neurodegenerative disease.
In a new study published in EMBO Molecular Medicine, Prof. Rivka Dikstein of the Weizmann Institute of Science and her team identified two small molecules that manage to penetrate the blood-brain barrier and reduce the levels of a defective protein that causes Huntington’s disease, an incurable neurodegenerative disorder. The new drugs not only slowed the progress of the disease in mouse models but even reversed some of its symptoms.
Mar 26, 2024...
Jerusalem, March 26, 2024 – The Blavatnik Family Foundation, the Israel Academy of Sciences and Humanities and The New York Academy of Sciences announced today the Laureates of the 2024 Blavatnik Awards for Young Scientists in Israel. This year’s Laureates, who will each receive $100,000, are:
Schraga Schwartz, PhD (Life Sciences) – Weizmann Institute of Science – Recognized for developing groundbreaking analytical methods to locate and quantify chemical changes in RNA. Professor Schwartz’s breakthroughs in understanding RNA modifications hold promise for treating genetic diseases and expanding the role of RNA editing beyond vaccine development.